NeuBase Makes Strategic Move; EZ Detect's Expanded Reach Fuels Biomerica
- August 03rd, 2023
- 405 views
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) announced a pause in its program development. Instead, NeuBase will explore strategic options, including acquisitions, mergers, and other transactions, with the goal of maximizing shareholder value.
According to the company, the outcome of this evaluation process remains uncertain, and there is no guarantee that any particular course of action will be taken.
$NBSE was trading at $1.26 in pre-market, up $0.02 (+1.61%).
In other news, Biomerica, Inc. (Nasdaq: BMRA) said that CVS Pharmacy has initiated the nationwide rollout of the Company's EZ Detect colorectal disease screening test across more than 7,000 CVS Pharmacy locations.
The EZ Detect product is expected to be available for purchase starting September, following its distribution to CVS Health centers. Moreover, Biomerica is collaborating with CVS Health to introduce another of its products in CVS pharmacies.
In pre-market, $BMRA was trading at $2.00, reflecting a gain of $0.54 (+36.98%) following the announcement.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer
Post Your Comments
Want To Find Some News?
Recent Posts
-
December 05th, 2025
FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 04th, 2025December 02nd, 2025Earnings Countdown: Salesforce, Snowflake, and Guidewire Take Center Stage
November 30th, 2025Wall Street Eyes CrowdStrike, Marvell Technology, and GitLab as Earnings Near
November 30th, 2025
Member Login